JJP Biologics: The European Commission Has Designated JJP-1212 as an Orphan Medicinal Product.
businesswire.com
news
2022-10-20 00:00:00

October 20, 2022 07:07 AM Eastern Daylight Time WARSAW, Poland--(BUSINESS WIRE)--JJP Biologics, a company that specializes in the development of proprietary biologic agents for personalized medicine approaches, has announced that the European Commission has approved the company's application for designation of its product candidate JJP-1212 as an orphan medicinal product for treatment of Linear IgA Bullous Dermatosis (LABD). Following the European Medicines Agency's recommendation, the European Commission has confirmed that the intention to treat this condition with JJP-1212 justified orphan drug status based on in vitro and in vivo non-clinical data showing the reduction in the influx of granulocytes into the basement membrane zone of the skin and reduction of inflammatory biomarkers, addressing the key elements of LABD skin blistering pathogenesis.
